Project ANAGRANINF:
The Technology Development Board (TDB) has penned an agreement with two companies and has sanctioned a grant of ₹75 Lakhs towards the project “ANAGRANINF for the development of a Novel Class of Antibiotics Against Gram-Negative Bacterial-Infections.
- The primary objective of this project is to develop a novel lead compound, particularly an antibiotic, adept at inhibiting the FabI enzyme and combatting critical gram-negative pathogens.
- Gram-negative bacteria have a much thinner peptidoglycan cell wall, but in addition they have an outer membrane containing lipopolysaccharides surrounding the cell and are consequently termed diderms.
- These bacteria have built-in abilities to find new ways to be resistant and can pass along genetic materials that allow other bacteria to become drug-resistant as well.
- It causes infections including pneumonia, bloodstream infections, wound or surgical site infections, and meningitis in healthcare settings.
- They are resistant to multiple drugs and are increasingly resistant to most available antibiotics.
